As of 2024-12-12, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (7.82) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.27 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -283.2%.
The range of the Relative Valuation is (4.95) - (7.85) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 23.6x | 22.2x |
| Forward P/E multiples | 14.9x - 25.2x | 24.9x |
| Fair Price | (4.95) - (7.85) | (7.82) |
| Upside | -215.9% - -283.9% | -283.2% |
| Date | P/E |
| 2024-11-25 | -10.43 |
| 2024-11-22 | -9.79 |
| 2024-11-21 | -8.94 |
| 2024-11-20 | -9.00 |
| 2024-11-19 | -9.06 |
| 2024-11-18 | -9.12 |
| 2024-11-15 | -9.05 |
| 2024-11-14 | -10.00 |
| 2024-11-13 | -10.72 |
| 2024-11-12 | -10.96 |
| 2024-11-11 | -10.96 |
| 2024-11-08 | -10.51 |
| 2024-11-07 | -10.48 |
| 2024-11-06 | -10.33 |
| 2024-11-05 | -10.00 |
| 2024-11-04 | -9.82 |
| 2024-11-01 | -9.67 |
| 2024-10-31 | -9.52 |
| 2024-10-30 | -9.76 |
| 2024-10-29 | -9.76 |
| 2024-10-28 | -9.76 |
| 2024-10-25 | -9.61 |
| 2024-10-24 | -9.76 |
| 2024-10-23 | -9.79 |
| 2024-10-22 | -10.21 |
| 2024-10-21 | -10.57 |
| 2024-10-18 | -10.57 |
| 2024-10-17 | -10.69 |
| 2024-10-16 | -10.90 |
| 2024-10-15 | -11.02 |
| 2024-10-14 | -10.75 |
| 2024-10-11 | -10.48 |
| 2024-10-10 | -9.85 |
| 2024-10-09 | -10.27 |
| 2024-10-08 | -10.66 |
| 2024-10-07 | -10.75 |
| 2024-10-04 | -11.50 |
| 2024-10-03 | -11.04 |
| 2024-10-02 | -11.65 |
| 2024-10-01 | -10.84 |
| 2024-09-30 | -10.75 |
| 2024-09-27 | -11.35 |
| 2024-09-26 | -12.04 |
| 2024-09-25 | -10.45 |
| 2024-09-24 | -9.67 |
| 2024-09-23 | -9.64 |
| 2024-09-20 | -10.12 |
| 2024-09-19 | -10.39 |
| 2024-09-18 | -10.36 |
| 2024-09-17 | -10.51 |